[en] Introduction: Patients with interstitial lung diseases (ILD) can be suspected to be at risk of experiencing a rapid flare-up due to COVID-19. However, no specific data are currently available for these patients.
<br />
<br />Methods: We retrospectively analyzed a cohort of 401 patients with ILD and determined the proportion of patients hospitalized for proven severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and specific symptoms of COVID-19.
<br />
<br />Results: We found that 1% of patients (n = 4) were hospitalized (1 in ICU) for COVID-19. In total, 310 of the 401 patients answered the phone call. Only 33 patients (0.08%) experienced specific symptoms of SARS-CoV-2 infection.
<br />
<br />Conclusion: Our study did not demonstrate any increased occurrence of severe COVID-19 in ILD patients compared to the global population. Based on our findings, we could not make any conclusion on the incidence rate of SARS-CoV-2 infection in patients with ILDs, or on the overall outcome of immunocompromised patients affected by COVID-19.
Disciplines :
Anesthesia & intensive care Immunology & infectious disease General & internal medicine
Author, co-author :
GUIOT, Julien ; Centre Hospitalier Universitaire de Liège - CHU > Département de médecine interne > Service de pneumologie - allergologie
HENKET, Monique ; Centre Hospitalier Universitaire de Liège - CHU > Département de médecine interne > Clinique de l'asthme
Frix, Anne-Noëlle ; Centre Hospitalier Universitaire de Liège - CHU > Département de médecine interne > Service de pneumologie - allergologie
Delvaux, Muriel ; Université de Liège - ULiège > Département de Psychologie > Psychologie de la santé
DENIS, Anna ; Centre Hospitalier Universitaire de Liège - CHU > > Pool
GILTAY, Laurie ; Centre Hospitalier Universitaire de Liège - CHU > Département infirmier > Service de pneumologie - allergologie
THYS, Marie ; Centre Hospitalier Universitaire de Liège - CHU > Département de gestion des systèmes d'informations (GSI) > Secteur exploitation des données
GESTER, Fanny ; Centre Hospitalier Universitaire de Liège - CHU > Département de médecine interne > Service de pneumologie - allergologie
MOUTSCHEN, Michel ; Centre Hospitalier Universitaire de Liège - CHU > Département de médecine interne > Service des maladies infectieuses - médecine interne
CORHAY, Jean-Louis ; Centre Hospitalier Universitaire de Liège - CHU > Département de médecine interne > Service de pneumologie - allergologie
LOUIS, Renaud ; Centre Hospitalier Universitaire de Liège - CHU > Département de médecine interne > Service de pneumologie - allergologie
Other collaborator :
LAMBERMONT, Bernard ; Centre Hospitalier Universitaire de Liège - CHU > Autres Services Médicaux > Service des soins intensifs
MALAISE, Olivier ; Centre Hospitalier Universitaire de Liège - CHU > > Service de rhumatologie
Language :
English
Title :
Single-center experience of patients with interstitial lung diseases during the early days of te COVID-19 pandemic.
COVID-19-Bulletin Epidemiologique Du 3 MAI 2020. [cited 2020 May 3]. Available from: https://epistat.wiv-isp.be/covid.
Memoli, M.J., Athota, R., Reed, S., Czajkowski, L., Bristol, T., Proudfoot, K., et al. The natural history of influenza infection in the severely immunocompromised vs nonimmunocompromised hosts. Clin Infect Dis 58:2 (2014 Jan 15), 214–224 Available from: https://academic.oup.com/cid/article-lookup/doi/10.1093/cid/cit725. (Accessed 27 April 2020)
Duchemann, B., Annesi-Maesano, I., Jacobe de Naurois, C., Sanyal, S., Brillet, P.-Y., Brauner, M., et al. Prevalence and incidence of interstitial lung diseases in a multi-ethnic county of Greater Paris. Eur Respir J, 50(2), 2017 Available from: https://erj.ersjournals.com/content/50/2/1602419. (Accessed 28 April 2020)
Coultas, D.B., Zumwalt, R.E., Black, W.C., Sobonya, R.E., The epidemiology of interstitial lung diseases. Internet Am J Respir Crit Care Med 150:4 (1994 Oct), 967–972 Available from: http://www.atsjournals.org/doi/abs/10.1164/ajrccm.150.4.7921471. (Accessed 28 April 2020)
Interim Guidance: Healthcare Professionals 2019-nCoV | CDC. [cited 2020 May 3]. Available from: https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-criteria.html.
Shi, Y., Wang, Y., Shao, C., Huang, J., Gan, Jianhe, Huang, X., et al. COVID-19 infection: the perspectives on immune responses. Cell Death Differ 27 (2020), 1451–1454, 10.1038/s41418-020-0530-3 Available from:. (Accessed 27 April 2020)
Monti, S., Balduzzi, S., Delvino, P., Bellis, E., Quadrelli, V.S., Montecucco, C., Clinical course of COVID-19 in a series of patients with chronic arthritis treated with immunosuppressive targeted therapies. Ann Rheum Dis. BMJ 79:5 (2020 May), 667–668, 10.1136/annrheumdis-2020-217424 Epub 2020 Apr 2.
Michaud, K., Wipfler, K., Shaw, Y., Simon, T.A., Cornish, A., England, B.R., et al. Experiences of patients with rheumatic diseases in the US during early days of the COVID-19 pandemic. ACR Open Rheumatol 2:6 (2020 Apr 20), 335–343 acr2.11148. Available from: https://onlinelibrary.wiley.com/doi/abs/10.1002/acr2.11148. (Accessed 3 May 2020)
Wong, A.W., Fidler, L., Marcoux, V., Johannson, K.A., Assayag, D., Fisher, J.H., et al. Journal Pre-proof Practical considerations for the diagnosis and treatment of fibrotic interstitial lung disease during the COVID-19 pandemic. Available from: https://doi.org/10.1016/j.chest.2020.04.019, 2020. (Accessed 28 April 2020)
Mihai, C., Dobrota, R., Schröder, M., Garaiman, A., Jordan, S., Becker, M.O., et al. COVID-19 in a patient with systemic sclerosis treated with tocilizumab for SSc-ILD. Ann Rheum Dis 79:5 (2020 May), 668–669 Available from: http://ard.bmj.com/lookup/doi/10.1136/annrheumdis-2020-217442. (Accessed 28 April 2020)
